Novel Contraceptive Nextstellis Gets FDA Approval
Nextstellis is a novel combined oral contraceptive pill containing drospirenone 3mg (DRSP) and estetrol 14.2mg.
Nextstellis is a novel combined oral contraceptive pill containing drospirenone 3mg (DRSP) and estetrol 14.2mg.
Discontinuation of oxytocin may lead to small increase in rate of cesarean section, decrease in fetal heart rate abnormalities
Consuming more than 50 mg of caffeine per day (the amount in about half a cup of coffee) linked to lower birth weight
The latest status on the Janssen vaccine; Updated guidance from the National Institutes of Health on COVID-19 antibody treatment; The FDA changes in-person mifepristone dispensing; A prefilled-syringe for Xolair injection is approved; And the AI world comes to colonoscopies.
Mifepristone is a progestin antagonist indicated, in a regimen with misoprostol, for the medical termination of intrauterine pregnancy through 70 days gestation.
Tisotumab vedotin is an investigational antibody-drug conjugate targeted to tissue factor.
The observed IgG transfer ratio demonstrates an infant antibody level about equal to maternal level
Review of 33 studies, including seven monitoring methods, shows no benefit from newer strategies
And passage of antibodies through the placenta and breastmilk appears to confer immunity to newborns
The io instrument processes a single-use cartridge that contains all reagents for testing collected vaginal swabs and male urine samples.